Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 2017
Daiichi Sankyo [DSK] (4568 JP) released Phase I data for DS-8201 at ESMO 2017 as follows: 32% overall response rate, 82% disease control rate. The...
158 Views
Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data
Chugai Pharmaceutical (4519 JP) announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi)...
253 Views
Chugai – Positive Data for Emicizumab from HAVEN 2
After Alecensa impressed in Phase III trials earlier this week, Chugai (4519 JP) had the added pleasure of seeing emicizumab do well in the second...
233 Views
Chugai Pharmaceutical: Update Ahead of Summer Data Releases
The excitement at Chugai Pharmaceutical (4519 JP) is palpable for all to see, and you quickly get the impression at any meeting that the company is...
151 Views
Chugai Pharmaceutical-Exceptionally Productive In-House R&D Driving Strong Growth
We publish an in-depth analysis of Chugai Pharmaceutical arriving at a DCF derived fair value of ¥ 4,200. Chugai’s strategic alliance with its...
207 Views